UCB

RATING

SECTOR

Biopharmaceutical

WEBSITE

CONTACT

Allée de la Recherche, 60
1070 Brussels
Belgium
Tel: +32 2 559 99 99
Fax: +32 2 559 99 00
E-mail: contactucb@ucb.com
RPM 0403.053.608 Brussels

STOCK EXCHANGE

LISTING

  • The London Stock Exchange’s FTSE4Good Index,
  • ECPI
  • Corporate Knights

EMPLOYEES

7,480 

CHIEF SUSTAINABILITY OFFICER

Veronique Toully

AWARDS

  • The EURORDIS Company Award has been awarded to UCB in recognition of our leadership in championing patient engagement via an Innovative Medicines Initiative (IMI) project called PARADIGM.
  • UCB colleagues in China received the ‘Best Company Award 2017’ at the Best of BenCham Award Ceremony, in ‘recognition of UCB’s Patient Value Strategy and impact on society’.

CONTENT SOURCE

FURTHER READING

N/A

UCB

SECTIONS :  Sustainability    Evaluation  •  Progress  •  Watch  •  Overview

Company Activity

With 7500 employees in approximately 40 countries, UCB is a global biopharmaceutical company headquartered in Brussels, Belgium which invests more than 20% of revenue in cutting-edge scientific research to meet unmet patient needs. They are focused on creating value for people living with severe diseases in immunology and neurology.
 
A few other reasons that make UCB an amazing place to work: 
Promising pipeline that includes several novel molecules; 
25% of 2018 revenue reinvested into Research & Development 
2018 Key Financials: €4.6 billion global revenue 
 
UCB – Inspired by patients and driven by science. At UCB, they put their  heart, soul, and skills into making a difference for people living with severe diseases. They look to transform patients’ lives by pushing the boundaries of what is possible. With us, their  talents make the most of who they are, unlocking innovation and setting new standards for patients.
 
Everything they do starts with a simple question: “How will this make a difference to the lives of people living with severe diseases?”
And to find the answers, they connect globally with patients and their families living with the physical and social burdens of severe disease. These connections give us new perspectives, drive their  innovation, and offer hope for a new generation of therapies that will help to transform lives

Company Sustainable Activity

According to UCB, a significant part of building trust is being transparent – being open and clearly disclosing what UCB does, how UCB works, where UCB is successful, and where challenges to UCB and the industry are present. This applies across all aspects of their global business. UCB has attempted to provide disclosure while referring to the Global Reporting Initiative Standards. In addition, the five CSR areas detailed in the 2017 Belgian legislation (environmental; social and employee; human rights; anti-corruption and bribery; and diversity and inclusion) are also disclosed in this 2018 Integrated Annual Report.
At UCB, they believe the company will be successful in the long-term by creating value for both their shareholders and for society as a whole. The voice of the stakeholders is essential in this journey and their recommendations to focus on important material aspects have been embedded in the corporate vision. The question “how will this create value for persons living with severe chronic diseases?” remains UCB’s guiding holistic principle to determine what will be the impact of the company’s decisions for patients, their business, UCB’s people, their environment and their society.

TARGETS 
UCB set the absolute target to reduce its water consumption by 20% by 2030, compared to the 2015 baseline. This target is quite ambitious, as UCB’s transformation to a leading biotech company will increasingly lead to the introduction of production processes, which typically tend to be more water demanding
UCB also set the absolute target to reduce its waste generation by 25% by 2030 compared to the 2015 baseline.
The COP21 ambition includes a reduction of GHG emissions by at least 25% by 2030 through a combination of policy and regulatory measures and market-based mechanisms, which most likely will impact future business practices and investments.
 
Even though their  main focus lies on reducing GHG emissions, they will need to compensate for the emissions they cannot reduce in the short term, in order to reach the goal of carbon neutrality by 2030 for the activities they control directly. That’s why UCB, in 2017, partnered with sustainability organizations dedicated to reforestation and environmental protection, that will coordinate their  carbon compensation efforts.

Certificates

100% manufacturing facilities certified ISO 14001

Sustainable Development Goals

How company covers SDGs

N/A

Progress

  • 7 135 GJ of current energy savings through energy efficient projects
  • 92% of electricity consumed by UCB originated from renewables sources
  • The overall energy consumption decreased by 5%
  • The usage of gas was reduced by 9%
  • The usage of electricity was reduced by 4%
  • In 2017, waste generated at the UCB facilities decreased by 19%
  • UCB globally managed to recover 91% of its waste
  • A three-year program to create intrinsically safe installations and to improve employee training launched in 2015, was continued in 2017.
  • In 2017, UCB spent more than € 7 million in community sponsorships and charitable donations worldwide, including € 1.6 million for the CSR patient initiatives.

UCB is a Bio-Pharmaceutical company focusing on neurological and immunology diseases. No certificates were traced for this company. UCB is contributing to SDG Goals, but still no clarity is given on its action plan. Although, we have some clue about their sustainable agenda, it is not enough to rate them higher.

Videos

Share this Post